|
|
Other links at Articles > Pharmacists |
| 3. |
Pyridoxine Metabolite Does Not Improve CABG Outcomes
|
|
|
Treatment with MC-1, a naturally occurring pyridoxine metabolite, does not reduce nonfatal MIs or cardiovascular deaths in intermediate- to high-risk patients undergoing coronary artery bypass grafting (CABG), the results of a randomized trial indicate. Reuters Health Information
|
|
|